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Introduction
Definition and classifications 
Infantile spasms (IS) are a unique form of seizure disorder that their occurrence is 
almost entirely limited to infancy (the first year of life) and they are refractory to 
conventional anticonvulsant drugs. IS usually are associated with developmental 
retardation or deterioration and a characteristic electroencephalographic (EEG) 
pattern (hypsarrhythmia) that together form a syndrome (1).
IS involves a sudden, generally bilateral and symmetric contractions of muscles 
of the neck, trunk, and extremities (1). Patients with IS can be classified into 
focal IS and diffuse groups according to different lateralizing signs, because the 
Abstract
Objective 
Infantile spasm (IS) is a convulsive disease characterized by brief, symmetric 
axial muscle contraction (neck, trunk, and/or extremities). IS is a type of seizure 
that was first described by West in 1841, who witnessed the seizure in his own 
son. West’s syndrome refers to the classic triad of spasms, characteristic EEG, 
and neurodevelopmental regression. Most cases involve flexors and extensors, 
but either of the types may be involved independently.
IS, as its name implies, most often occurs during the first year of life with an 
incidence of approximately 1 per 2000-4000 live births. Most, but not all, patients 
with this disorder have severe EEG abnormalities; this pattern was originally 
referred to as hypsarrhythmia by Gibbs and Gibbs. Cases with known etiology 
or signs of brain damage are considered as symptomatic. The Overall prognosis 
of the disease is poor. Peak onset age of the epileptic syndrome is 3 to 7 months, 
which mainly occurs before 2 years of age in 93% of patients. Hypsarrhythmia 
is the EEG hallmark of IS, which comprised a chaotic, bilaterally asynchronous 
high-voltage polyspike, and slow wave discharges interspersed with multifocal 
spikes and slow waves.
Etiological classification is as follows: 1) Symptomatic: with identifiable prenatal, 
perinatal, and postnatal causes with developmental delay at the presentation time; 
2) Cryptogenic: unknown underlying cause, normal development at the onset of 
spasms, normal neurological exam and neuroimaging, and no abnormality in the 
metabolic evaluation; 3) Idiopathic: pure functional cerebral dysfunction with 
complete recovery, no residual dysfunction, normal neuroimaging and normal 
etiologic evaluation, and normal neurodevelopment. 
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classification provides practical information on the 
long-term outcome and treatment strategy (2). The type 
of seizure depends on which muscle groups (flexor or 
extensor) are predominantly affected and on the extent 
of the contraction. Flexor spasms have long been 
considered as the most characteristic type of seizure and 
thus, they have been predominantly featured in naming 
the syndrome. Flexor spasms (42% of cases) and mixed 
flexor-extensor spasms (50% of cases) included the most 
common types (1).
IS most commonly develops between 3 and 8 months 
of age, with only 8% of cases first being encountered 
in infants older than 1 year of age. (3). The EEG has 
the characteristics of hypsarrhythmia, a disorganized 
interictal pattern that consists of random high-voltage 
slow waves and spikes. In addition to classic EEG 
pattern, there are several hypsarrhythmia variants, which 
have been grouped together and termed as “modified 
hypsarrhythmia” (4,5).
ISs are classified as cryptogenic or symptomatic. 
Cryptogenic spasms, a minority of the cases of IS, occur 
in infants with normal birth and development until 
the onset of seizure, in whom no clear cause for the 
convulsions can be identified. A variety of prenatal and 
perinatal insults are accounted for the majority of cases 
in the symptomatic group (3,6).
Etiologic factors
ISs have multiple causes, and their mechanism is at 
best, incompletely understood(1). Although the unifying 
epileptogenic mechanism is unknown, various underlying 
disorders cause ISs. These disorders are often classified 
into prenatal, perinatal and postnatal groups. Accounting 
for over 40 percent of total cases, prenatal etiologies 
include CNS malformations (focal cortical dysplasia, 
lissencephaly, holoprosencephaly, hemimegalencephaly, 
Callosal agenesis/Aicardi syndrome), chromosomal 
abnormalities (trisomy 21, Miller-Dieker syndrome), 
single-gene errors, neurocutaneous syndrome (TS, NF1, 
incontinentia pigmenti), congenital central nervous 
system infections (TORCH), and rarely, in-born error 
of metabolism. Perinatal precipitants include hypoxic 
ischemic encephalopathy and hypoglycemia.
Finally, postnatal factors include intracranial infections, 
hypoxic-ischemic insults, and brain tumors. Overall, 
cortical malformations, hypoxic-ischemic, and tuberous 
sclerosis are the most common known associated 
disorders (4).
Diagnostic evaluations
In a child with suspected IS, an EEG is needed to confirm 
the presence of hypsarrhythmia. If EEG remains normal 
with no features of hypsarrhythmia or its variants, it 
should be repeated in 1-2 weeks, and once the diagnosis 
of IS established, the evaluations shift to classification 
and determination of the underlying etiology. When the 
history is being taken, special attention should be paid 
to prenatal issues and prior development. Examination 
may reveal dysmorphic features, neurologic signs, or 
neurocutaneous stigmata.
Neuroimaging is the most important diagnostic test 
that leads to confirmation of etiology in approximately 
70% of cases. MRI is the initial neuroimaging modality 
of choice, with higher sensitivity in detecting subtle 
structural abnormality compared to CT. PET technique 
should be considered in medically intractable cases 
when focal EEG or clinical examination raise suspicion 
for a focal CNS process that may be amenable to surgical 
resection (4).
If neuroimaging or clinical examination raises suspicion 
of a genetic disorder, then targeted genetic testing 
may be indicated. Result of metabolic and genetic 
testing combined may determine the etiology in an 
additional 10% of cases. However, if the examination 
and neuroimaging are not revealing, a basic metabolic 
screen, including electrolytes, glucose, pyrovate lactate, 
ammonia, plasma amino acid, and urine organic acid is 
recommended (4).
Genetic testing may be helpful in refractory cases without 
a known cause (4) (Figure1). Some other conditions may 




One-third of the patients died before 3 years of age 
and 50% before 10 years of age. Visual and auditory 
defects are present in one-third to one-half of affected 
children. Mental retardation was observed in 71 to 
90 percent of patients(1). There is growing evidence 
that longer duration of spasms is associated with less 
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neurodevelopmental outcomes(8). Currently, there is 
no evidence that medical or surgical treatment of IS can 
significantly alter long-term outcome(9).
A psychiatric disorder was diagnosed in 28% of patients 
and IS may play a significant role in the etiology 
of autism. Epilepsy will be seen in other forms of 
seizure other than IS in approximately 50% to 60% of 
children over the coming years. A focal lesion is often 
associated with a poor neurodevelopmental outcome (1). 
Spontaneous remission of spasms and disappearance of 
hypsarrhythimia in untreated patients have been reported 
in 25% of children by 1 year of age, but overall, the 
developmental outcome in IS is poor (4).
Pathophysiology
Several hypotheses have been suggested, including 
brainstem dysfunction of serotonergic neurons or 
abnormal interaction between the brainstem and a focal 
or diffuse cortical abnormality, abnormalities in cortical-
subcortical interactions. Immunologic dysfunction in the 
hypothalamic-adrenal-pituitary (HPA) axis has also been 
investigated. One hypothesis proposes that stress from 
variable causes in early development leads to the release 
of corticotropin-releasing hormone (CRH), which then 
causes increased neuronal excitability and seizures. 
Supporting evidence for this CRH excess hypothesis are 
decreased levels of ACTH in the cerebrospinal fluid of 
patients with ISs and the known efficiency of ACTH and 
glucocorticoids in the treatment of IS (4).
Treatment
ISs are resistant to most of the conventional antiepileptic 
drugs. Only ACTH, corticosteroids, and vigabatrin have 
conclusively demonstrated effectiveness. The most 
commonly used drug is ACTH in doses of 20 to 40 IU/
day (1). Low-dose ACTH may be as effective as high-
dose ACTH. In comparison with other agents, ACTH is 
suggested to be more effective than oral corticosteroids, 
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Fig 1. Suggested clinical evaluation and work-up of infantile spasms IS, 
infantile spasms; PET, positron emission tomography(4)
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and compared to vigabatrin, it has improved outcome 
in the cessation of the spasms. For decreasing serious 
adverse events, such as intracranial hemorrhage, 
brain atrophy, Cushing syndrome, infection, weight 
gain and hypertension, short-term low dose therapy is 
recommended (10-12). In one study by Fukui et al., it 
has been shown that ACTH therapy can induce partial 
seizures for the following reasons: (1) seizure appeared 
only during ACTH therapy; (2) no new epileptic focus 
was shown by EEG, MRI, or SPECT; and (3) seizures 
were different from the epileptic spasms (13).
Corticosteroids are also effective; Prednisolone, 
hydrocortisone, and dexamethazone are most commonly 
recommended. Side-effects, such as hypertension, brain 
shrinking, cardiac hypertrophy, and adrenocortical 
hyporesponsiveness were related to the dose and these 
were therefore minimized by the drug regimen. Although 
synthetic ACTH (tetracosactrin) seems to produce more 
serious side-effects than natural corticotropin, and most 
authors have reported that it can be used regularly 
without major problems (1).
Vigabatrin has been used in the treatment of IS in Europe 
since 1990, and seems highly effective in spasms due 
to tuberous sclerosis. Benzodiazepines, most notably 
Nitrazepam may be effective in bringing the spasms 
under control, with relatively few side effects. Most 
investigators consider the benzodiazepine to be less 
active than steroids (14).
Other drugs, including Valproic acid, Zonisamide, 
Felbamate, Lamotrigine, Topiramate, and ketogenic 
diet (KD) may provide more benefit in reducing spasms 
and, therefore, are often used after hormonal therapy 
and vigabatrin (4). In a randomized controlled trial of 
Flunarizine as add-on therapy and effect on cognitive 
outcome in IS, failed to show a protective effect (15). 
KD is an effective treatment for refractory epilepsy 
including ISs. In one study, 17 patients were treated by 
KD for IS. After one month of treatment with KD, 35% 
of patients were seizure free, while 65% were seizure 
free after the third month. An early use (before 1-year-
old) of KD and the use of KD after vigabatrin and steroid 
can be effective, and Felbamate causes an increase in the 
responder rate after the use of KD (16,17).
In a randomized controlled clinical trial, 60 patients with 
newly diagnosed and previously untreated IS, received 
0.5-1 mg/kg Nitrazepam in three daily doses or 40 IU 
depot ACTH as a single morning dose. Following the 
treatments, at the end of the 6-week therapy, optimal 
response was obtained in 63% of patients of Nitrazepam 
group and 30% of patients of ACTH group. This finding 
supports the belief that Nitrazepam is an effective and 
possibly safer therapy than ACTH (18). In a descriptive 
study done on 60 infants aged 2-24 months in the Pediatric 
Neurology Department of Mofid Children’s Hospital 
during two years, 80% of patients were symptomatic and 
20% were cryptogenic, based on clinical manifestations. 
Fifty-eight percent were flexor type, 10% extensor, and 
32% mixed type. In all patients’ EEG, hypsarrhythmia 
was seen. Brain CT scan in 11 cases showed brain atrophy 
and in other cases was normal (19). in other descriptive 
study done on 40 cases of tuberous sclerosis in the 
Pediatric Neurology Department of Mofid Children’s 
Hospital, the most common clinical manifestation was 
seizure, and the most common type of seizure was 
myoclonic. In 19 cases with tuberous sclerosis, in the 
first year of life, seizure was appeared as ISs (20). The 
optimum evaluation and treatment of children with ISs 
is unknown. To aid in the development of a standardized 
approach for ISs, members of the Child Neurology 
Society were surveyed to determine common practice. 
The survey had 222 responders with a responder rate 
of 18.5%. It is important that the diagnostic evaluation 
and the use of first-line treatments varied among the 
responders. Thus, future clinical trials will require 
multicenter collaboration. An important first step in 
such collaboration is to standardize the evaluation and 
treatment of IS within and between participating centers 
(21, 22).
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